Shenzhen TargetRx, Inc.

ACTIVE

广东省深圳市, 广东省, Chinawww.tjrbiosciences.comHolding1–10 employeesEstablished: 2014-08-04

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2014

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

76.9%

Phase 2

15.4%

Phase 3

7.7%

Trial Status Distribution

Active, not recruiting

30.8%

Completed

38.5%

Recruiting

30.8%

Clinical Trials

Trials sponsored by this organization (13)

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

Phase 1

Recruiting

interventional

Jul 202490 participants

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Phase 1

Recruiting

interventional

Jul 202490 participants

TGRX-326 Pharmacokinetic Mass Balance

Phase 1

Completed

interventional

Jun 20246 participants

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Phase 1

Recruiting

interventional

Mar 202430 participants

TGRX-326 Pharmacokinetic Drug Interaction

Phase 1

Completed

interventional

Mar 202434 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations

Shenzhen TargetRx, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (13)

TGRX-678 Pharmacokinetic Mass Balance

TGRX-678 Phase I Oral Pharmacokinetic Study

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

TGRX-326 Pharmacokinetic Mass Balance

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

TGRX-326 Pharmacokinetic Drug Interaction

Approvals

News